Penumbra Inc at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone. I'm Robbie Marcus, the medtech analyst here at JPMorgan. I'm very happy to present Penumbra, the next company, and a warm welcome to Adam Elsesser, the founder, Chairman and CEO of Penumbra. Adam?
Good afternoon. I want to thank JPMorgan for including us in this year's meeting. And of course, thank you, Robbie, for your coverage of Penumbra. Here's our safe harbor disclosure.
Since our founding in 2004, Penumbra's vision has been to build a business that always focuses on bringing new treatments to help as many people as possible. For us, this typically means finding an area that no other company is in or has succeeded in and working tirelessly to innovate for years to perfect the treatment.
We have built a purposeful structure at Penumbra and culture that allows us to do this over and over and in a way that we can scale as we grow. Our company has achieved a cumulative annual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
